Results 191 to 200 of about 4,040 (201)

Effect of Meropenem-Vaborbactam vs Piperacillin-Tazobactam on Clinical Cure or Improvement and Microbial Eradication in Complicated Urinary Tract Infection

JAMA - Journal of the American Medical Association, 2018
Tanaya Bhowmick, Symeon Metallidis, Jose Vazquez   +2 more
exaly  

Ceftazidime/Avibactam, Meropenem/Vaborbactam, or Both? Clinical and Formulary Considerations

Clinical Infectious Diseases, 2019
Jason M Pogue, Robert A Bonomo
exaly  

Activity of Meropenem-Vaborbactam in Mouse Models of Infection Due to KPC-Producing Carbapenem-Resistant Enterobacteriaceae

Antimicrobial Agents and Chemotherapy, 2018
Mojgan Sabet, Olga Lomovskaya
exaly  

Activity of Meropenem-Vaborbactam against Pseudomonas aeruginosa and Acinetobacter baumannii in a Neutropenic Mouse Thigh Infection Model

Antimicrobial Agents and Chemotherapy, 2019
Mojgan Sabet
exaly  

Meropenem-Vaborbactam Resistance Selection, Resistance Prevention, and Molecular Mechanisms in Mutants of KPC-Producing Klebsiella pneumoniae

Antimicrobial Agents and Chemotherapy, 2017
Olga Lomovskaya
exaly  

Cloxacillin/meropenem/vaborbactam

Reactions Weekly
openaire   +1 more source

Overview of meropenem-vaborbactam and newer antimicrobial agents for the treatment of carbapenem-resistant <em>Enterobacteriaceae</em>

Infection and Drug Resistance, 2018
Oryan Henig, Keith S Kaye, Lindsay A Petty   +2 more
exaly  

Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of Vaborbactam and Meropenem Alone and in Combination following Single and Multiple Doses in Healthy Adult Subjects

Antimicrobial Agents and Chemotherapy, 2018
exaly  

Meropenem-vaborbactam: a carbapenem and beta-lactamase inhibitor with activity against carbapenem-resistant Enterobacteriaceae

European Journal of Clinical Microbiology and Infectious Diseases, 2018
exaly  

Meropenem/vaborbactam (Vabomere) for complicated urinary tract infection.

The Medical letter on drugs and therapeutics, 2018
openaire   +1 more source